Brought to you by 
Takeda and enGene partner
15 Jan 2016
Executive Summary
Takeda Pharmaceutical Co. Ltd. and enGene Inc. will work together to develop new gastrointestinal disease therapies based on enGene's "Gene Pill" oral delivery platform that delivers therapeutic genes to cells of the gut lining.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda and enGene partner
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice